ATE339406T1 - Chinazoline verbindungen als heilmittel - Google Patents
Chinazoline verbindungen als heilmittelInfo
- Publication number
- ATE339406T1 ATE339406T1 AT00958907T AT00958907T ATE339406T1 AT E339406 T1 ATE339406 T1 AT E339406T1 AT 00958907 T AT00958907 T AT 00958907T AT 00958907 T AT00958907 T AT 00958907T AT E339406 T1 ATE339406 T1 AT E339406T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- chinazoline
- remedies
- formulaand
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15562399P | 1999-09-23 | 1999-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE339406T1 true ATE339406T1 (de) | 2006-10-15 |
Family
ID=22556162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00958907T ATE339406T1 (de) | 1999-09-23 | 2000-09-18 | Chinazoline verbindungen als heilmittel |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6399603B1 (de) |
| EP (1) | EP1218358B1 (de) |
| JP (1) | JP2003509501A (de) |
| AT (1) | ATE339406T1 (de) |
| AU (1) | AU7031500A (de) |
| DE (1) | DE60030741T2 (de) |
| ES (1) | ES2270867T3 (de) |
| WO (1) | WO2001021598A1 (de) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1088821A1 (de) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Pharmazeutisch wirksamer Sulfonamid Derivate |
| JP2003520854A (ja) * | 2000-01-27 | 2003-07-08 | サイトビア インコーポレイテッド | カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換ニコチンアミドおよび類似物およびそれらの使用 |
| EP1283199A4 (de) * | 2000-05-16 | 2003-12-17 | Takeda Chemical Industries Ltd | Antagonisten des melanin-konzentrierenden hormons |
| AU7622500A (en) * | 2000-09-29 | 2002-07-01 | Neurogen Corp | High affinity small molecule c5a receptor modulators |
| US20040198650A1 (en) * | 2001-03-29 | 2004-10-07 | Poul Jensen | Means for inhibiting proteolytical processing of parkin |
| AT413485B (de) * | 2001-04-09 | 2006-03-15 | Hemoteq Gmbh | Mit einem pharmazeutikum beschichteter stent |
| US7148244B2 (en) | 2001-04-26 | 2006-12-12 | Nippon Shinyaku Co. Ltd. | Medicines in controlling Vpr function |
| JP2005514330A (ja) * | 2001-09-24 | 2005-05-19 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病治療のための置換アミン |
| WO2003055866A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| MXPA04009541A (es) * | 2002-03-29 | 2005-01-25 | Chiron Corp | Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf. |
| US8299108B2 (en) * | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
| EP1398032A1 (de) * | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxochinazoline, die an den LXR Kernrezeptor binden |
| WO2004087153A2 (en) * | 2003-03-28 | 2004-10-14 | Chiron Corporation | Use of organic compounds for immunopotentiation |
| ATE440825T1 (de) | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| KR20060073930A (ko) * | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| WO2005030131A2 (en) * | 2003-09-23 | 2005-04-07 | Replidyne, Inc | Bis-quinazoline compounds for the treatment of bacterial infections |
| EP1682126B1 (de) * | 2003-10-16 | 2009-07-01 | Novartis Vaccines and Diagnostics, Inc. | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
| WO2006082001A1 (en) | 2005-02-07 | 2006-08-10 | F.Hoffmann-La Roche Ag | Heterocyclic substituted phenyl methanones as inhibitors of the glycine transporter 1 |
| AU2007231594A1 (en) * | 2006-03-23 | 2007-10-04 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
| US20110053932A1 (en) * | 2007-06-21 | 2011-03-03 | Irm Llc | Protein Kinase Inhibitors and Methods for Using Thereof |
| WO2009084695A1 (ja) | 2007-12-28 | 2009-07-09 | Carna Biosciences Inc. | 2-アミノキナゾリン誘導体 |
| JP5370957B2 (ja) * | 2008-08-20 | 2013-12-18 | 学校法人日本大学 | アポトーシス抑制剤 |
| WO2010045374A1 (en) * | 2008-10-15 | 2010-04-22 | Gilead Palo Alto, Inc. | 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors |
| WO2011025859A1 (en) | 2009-08-26 | 2011-03-03 | Cylene Pharmaceuticals, Inc. | Condensed quinolines as protein kinase modulators |
| US9051296B2 (en) | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
| CN101919833B (zh) * | 2010-07-16 | 2012-01-11 | 暨南大学 | 一种芳香类化合物作为制备Caspase 3抑制剂的用途 |
| EA201590916A1 (ru) | 2012-11-09 | 2016-02-29 | Корнэлл Юниверсити | Низкомолекулярные ингибиторы malt1 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| ES3069593T3 (en) * | 2013-08-23 | 2026-06-09 | Neupharma Inc | Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| CA2972014C (en) | 2014-12-24 | 2019-09-24 | Gilead Sciences, Inc. | Fused pyrimidine compounds for the treatment of hiv |
| TWI770552B (zh) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| SG11201705184PA (en) | 2014-12-24 | 2017-07-28 | Gilead Sciences Inc | Isoquinoline compounds for the treatment of hiv |
| EP3270694A4 (de) | 2015-02-17 | 2018-09-05 | Neupharma, Inc. | Bestimmte chemische einheiten, zusammensetzungen und verfahren |
| CN108299425B (zh) | 2015-03-24 | 2020-09-18 | 上海璎黎药业有限公司 | 稠环衍生物、其制备方法、中间体、药物组合物及应用 |
| CN106220644B (zh) * | 2015-04-24 | 2020-07-31 | 广州再极医药科技有限公司 | 稠环嘧啶氨基衍生物﹑其制备方法、中间体、药物组合物及应用 |
| US10494378B2 (en) * | 2015-07-21 | 2019-12-03 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof |
| US11129824B2 (en) | 2015-12-17 | 2021-09-28 | Biokine Therapeutics Ltd. | Small molecules for inhibiting chemokine activity and/or cancer cells growth |
| US10646465B2 (en) | 2015-12-17 | 2020-05-12 | Biokine Therapeutics Ltd. | Small molecules against cancer |
| CN109843858B (zh) | 2016-08-15 | 2023-05-05 | 润新生物公司 | 某些化学实体、组合物及方法 |
| CN109715163B (zh) | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
| WO2018203219A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| EP4563150A3 (de) | 2019-05-13 | 2025-07-23 | Novartis AG | Neue kristalline formen von n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonikotinamid als raf-hemmer zur behandlung von krebs |
| CA3090315C (en) | 2019-05-15 | 2023-09-19 | Biokine Therapeutics Ltd. | 8-phenoxy-quinolinone derivatives for treating cancer, inhibiting chemokine activity and/or inducing cell death |
| WO2021175155A1 (zh) * | 2020-03-06 | 2021-09-10 | 广州再极医药科技有限公司 | 噻吩并嘧啶类衍生物及其制备方法 |
| CN118027024A (zh) * | 2022-11-14 | 2024-05-14 | 南京同诺康医药科技有限公司 | 吡啶并[1,2-a]嘧啶-4-酮衍生物及其制备方法和用途 |
| EP4722198A1 (de) * | 2024-10-04 | 2026-04-08 | Technische Universität München, in Vertretung des Freistaats Bayern | Verbindungen zur verwendung bei der behandlung von bakteriellen erkrankungen und infektionen |
| WO2026148270A1 (en) * | 2025-01-03 | 2026-07-09 | Resero Therapeutics, Llc | Polo-like kinase 1 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2488379A (en) * | 1949-11-15 | Quinazoline derivatives | ||
| GB585363A (en) * | 1944-08-31 | 1947-02-05 | Erancis Henry Swinden Curd | New heterocyclic compounds |
| US4079057A (en) * | 1977-05-31 | 1978-03-14 | Bristol-Myers Company | Selective immunosuppressive agents |
| DD225131A1 (de) * | 1984-01-30 | 1985-07-24 | Akad Wissenschaften Ddr | Verfahren zur herstellung 2-substituierter 3,4-dihydrochinazolin-4-one |
| TW334434B (en) * | 1995-05-16 | 1998-06-21 | Kanebo Ltd | Novel quinazoline compound and anti-tumor agent |
| WO2000015604A1 (fr) * | 1998-09-11 | 2000-03-23 | Kyorin Pharmaceutical Co., Ltd. | Derives de diesters maloniques et leur procede d'obtention |
| AU5648599A (en) * | 1998-09-11 | 2000-04-03 | Kyorin Pharmaceutical Co. Ltd. | Phosphonic ester derivatives and process for producing the same |
-
2000
- 2000-09-18 ES ES00958907T patent/ES2270867T3/es not_active Expired - Lifetime
- 2000-09-18 EP EP00958907A patent/EP1218358B1/de not_active Expired - Lifetime
- 2000-09-18 JP JP2001524977A patent/JP2003509501A/ja active Pending
- 2000-09-18 WO PCT/GB2000/003555 patent/WO2001021598A1/en not_active Ceased
- 2000-09-18 DE DE60030741T patent/DE60030741T2/de not_active Expired - Lifetime
- 2000-09-18 AU AU70315/00A patent/AU7031500A/en not_active Abandoned
- 2000-09-18 AT AT00958907T patent/ATE339406T1/de not_active IP Right Cessation
- 2000-09-22 US US09/668,322 patent/US6399603B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU7031500A (en) | 2001-04-24 |
| EP1218358B1 (de) | 2006-09-13 |
| JP2003509501A (ja) | 2003-03-11 |
| US6399603B1 (en) | 2002-06-04 |
| WO2001021598A1 (en) | 2001-03-29 |
| DE60030741T2 (de) | 2007-09-06 |
| DE60030741D1 (de) | 2006-10-26 |
| EP1218358A1 (de) | 2002-07-03 |
| ES2270867T3 (es) | 2007-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60030741D1 (de) | Chinazoline verbindungen als heilmittel | |
| DE60038183D1 (de) | Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe | |
| ATE329897T1 (de) | Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen | |
| DK1200412T3 (da) | Antiproliferative imidazolforbindelser | |
| NO324227B1 (no) | Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer | |
| DE60034240D1 (de) | Drogen zur behandlung maligner tumoren | |
| PT915898E (pt) | Forma i cristalina de claritromicina | |
| ATE355288T1 (de) | Verbindungen und therapeutische methoden | |
| ATE284861T1 (de) | N-aralkylaminotetraline als neuropeptid-y-y5- rezeptorliganden | |
| PT934065E (pt) | Compostos farmaceuticos | |
| DE60105025D1 (de) | Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie | |
| NO20020282D0 (no) | Nytt difenylpiperidinderivat | |
| DE69729183D1 (de) | Als entzündungshemmende mittel nützliche dihydrobenzofurane und verwandte verbindungen | |
| SG162614A1 (en) | Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors | |
| GB9907571D0 (en) | Compounds | |
| EP1142573A4 (de) | Antibakterielle medizinische zusammenstellung | |
| SE0003476D0 (sv) | Compounds | |
| AU2001246999A1 (en) | New neurokinin antagonists for use as medicaments | |
| SE0004827D0 (sv) | Therapeutic compounds | |
| DE69626544D1 (de) | Arzneistoffe | |
| NO20020914D0 (no) | Alkoksy-substituerte benzimidazolforbindelser, preparater inneholdende slike samt anvendelser derav | |
| DE60114597D1 (de) | Naphthamid-neurokinin antagonisten zur verwendung als medikamente | |
| NO20014889D0 (no) | Fremgangsmåte for fremstilling av medisinske midler | |
| PT1551850E (pt) | 2 oxo-voruscharina e seus derivados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |